Alkem Lab
Drug Manufacturers - Specialty & Generic · ALKEM
Large CapHealthcareMature Stable
Sandeep Singh
Managing Director · Transactional
Company DNA
Hierarchical
About
Alkem Lab is a Large Cap company in the Healthcare sector, listed on NSE as ALKEM. With a market cap of ₹65K Cr and revenue of ₹13K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Operates as a high-promoter-holding entity with traditional management styles characteristic of established Indian pharma manufacturing houses. Its strategic mandate: Needs to shift from heavy generic dependency toward high-value specialty products to defend margins against intense domestic and export pricing pressures.
FAQ
What kind of company is Alkem Lab?
Alkem Lab is a Large Cap Healthcare company (ALKEM) in the Mature Stable phase with a market cap of ₹65K Cr. It is classified as Hierarchical in culture.
What is Alkem Lab's culture and work environment like?
Alkem Lab has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Operates as a high-promoter-holding entity with traditional management styles characteristic of established Indian pharma manufacturing houses.
Who leads Alkem Lab?
Alkem Lab is led by Sandeep Singh (Managing Director), a Transactional leader with 18 years of experience.
What are Alkem Lab's financials?
Alkem Lab reported revenue of ₹13K Cr in FY25 with a 5-year revenue CAGR of 6.8%. Operating margin: 17.1%. Market cap: ₹65K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
Operates as a high-promoter-holding entity with traditional management styles characteristic of established Indian pharma manufacturing houses.
Mandate
Needs to shift from heavy generic dependency toward high-value specialty products to defend margins against intense domestic and export pricing pressures.
Needs to shift from heavy generic dependency toward high-value specialty products to defend margins against intense domestic and export pricing pressures.
Financials
Revenue FY25₹13K Cr
PAT FY25₹2K Cr
Rev CAGR 5Y6.8%
OPM17.1%
NPM16.9%
ROE18.1%
ROCE15.9%
P/E27
Fwd P/E28
P/B4.8
D/E17.1
Mkt Cap₹65K Cr
Promoter62.9%
Institutional25.1%
Similar Culture
Could You Lead Alkem Lab?
Take the Genome Benchmark →